AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,290,875 | -23.1% | 352,868 | -20.6% | 0.00% | 0.0% |
| Q2 2023 | $5,579,290 | +43.6% | 444,211 | +26.8% | 0.00% | 0.0% |
| Q1 2023 | $3,884,506 | -20.0% | 350,271 | -11.9% | 0.00% | – |
| Q4 2022 | $4,853,328 | -31.3% | 397,488 | -41.2% | 0.00% | -100.0% |
| Q3 2022 | $7,062,000 | +273.5% | 676,450 | +284.2% | 0.00% | – |
| Q2 2022 | $1,891,000 | -22.9% | 176,076 | -32.1% | 0.00% | – |
| Q1 2022 | $2,454,000 | -69.4% | 259,261 | -62.7% | 0.00% | – |
| Q4 2021 | $8,018,000 | +80.5% | 694,266 | +49.2% | 0.00% | – |
| Q3 2021 | $4,443,000 | +28.3% | 465,269 | +29.5% | 0.00% | – |
| Q2 2021 | $3,464,000 | -55.9% | 359,282 | -54.8% | 0.00% | -100.0% |
| Q1 2021 | $7,853,000 | -54.1% | 794,859 | +7.3% | 0.00% | 0.0% |
| Q4 2020 | $17,108,000 | +232.6% | 740,938 | +103.4% | 0.00% | – |
| Q3 2020 | $5,143,000 | -32.6% | 364,201 | -28.0% | 0.00% | -100.0% |
| Q2 2020 | $7,627,000 | +132.2% | 505,683 | +42.2% | 0.00% | +100.0% |
| Q1 2020 | $3,285,000 | +40.9% | 355,577 | +48.5% | 0.00% | – |
| Q4 2019 | $2,331,000 | -36.5% | 239,425 | -47.7% | 0.00% | -100.0% |
| Q3 2019 | $3,669,000 | -85.6% | 457,512 | -77.6% | 0.00% | -66.7% |
| Q2 2019 | $25,462,000 | +49.1% | 2,040,418 | +62.5% | 0.00% | -57.1% |
| Q1 2019 | $17,076,000 | +329.2% | 1,255,600 | +202.3% | 0.01% | +600.0% |
| Q4 2018 | $3,979,000 | -52.5% | 415,388 | -40.1% | 0.00% | -66.7% |
| Q3 2018 | $8,378,000 | -74.3% | 693,023 | -66.8% | 0.00% | -72.7% |
| Q2 2018 | $32,578,000 | -58.8% | 2,085,637 | -60.3% | 0.01% | -60.7% |
| Q1 2018 | $79,044,000 | +65.0% | 5,255,624 | +57.9% | 0.03% | +64.7% |
| Q4 2017 | $47,901,000 | -2.9% | 3,328,713 | +1.8% | 0.02% | -10.5% |
| Q3 2017 | $49,319,000 | +317.4% | 3,270,428 | +178.7% | 0.02% | +280.0% |
| Q2 2017 | $11,816,000 | +233.2% | 1,173,391 | +135.9% | 0.01% | +150.0% |
| Q1 2017 | $3,546,000 | +19.6% | 497,400 | -16.6% | 0.00% | 0.0% |
| Q4 2016 | $2,965,000 | -46.7% | 596,673 | -20.7% | 0.00% | -33.3% |
| Q3 2016 | $5,565,000 | +123.9% | 752,000 | +65.2% | 0.00% | +50.0% |
| Q2 2016 | $2,485,000 | -78.6% | 455,200 | -66.9% | 0.00% | -71.4% |
| Q1 2016 | $11,607,000 | +28.7% | 1,373,652 | +47.8% | 0.01% | +75.0% |
| Q4 2015 | $9,016,000 | +74.3% | 929,520 | +151.3% | 0.00% | +300.0% |
| Q3 2015 | $5,174,000 | -57.9% | 369,833 | -57.4% | 0.00% | -80.0% |
| Q2 2015 | $12,294,000 | -6.3% | 868,786 | -28.0% | 0.01% | 0.0% |
| Q1 2015 | $13,127,000 | +60.0% | 1,206,552 | +22.4% | 0.01% | +150.0% |
| Q4 2014 | $8,203,000 | +352.7% | 985,941 | +223.5% | 0.00% | – |
| Q3 2014 | $1,812,000 | +100.4% | 304,737 | +12.6% | 0.00% | – |
| Q2 2014 | $904,000 | +62.3% | 270,545 | +0.5% | 0.00% | – |
| Q1 2014 | $557,000 | -33.9% | 269,236 | -24.9% | 0.00% | – |
| Q4 2013 | $843,000 | +7.7% | 358,563 | +6.2% | 0.00% | – |
| Q3 2013 | $783,000 | +40.6% | 337,565 | +41.2% | 0.00% | – |
| Q2 2013 | $557,000 | – | 239,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |